-
Sunshine Guojian Pharmaceutical’s SSGJ-608 Files for NMPA Approval in Plaque Psoriasis
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530), has announced that the National Medical Products Administration (NMPA) has accepted its market filing for the drug candidate SSGJ-608 for review. The company is seeking regulatory approval for the anti-IL-17A monoclonal antibody to treat moderate…
-
Sunshine Guojian Pharmaceutical Secures NMPA Approval for Clinical Trials of SSGJ-626 in Lupus Indications
•
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its monoclonal antibody, SSGJ-626. This BDCA2-targeted mAb will now enter trials for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), indications that have…
-
Sunshine Guojian Pharma Reports Q3 Revenue Growth and Advances in Clinical Trials
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530), has released its financial report for the third quarter of 2024. The company reported revenues of RMB 939 million (USD 131.8 million) for the period, marking a 28.58% increase year-on-year. The net profit attributable to…
-
3SBio Subsidiary Achieves Milestone in Phase III Psoriasis Trial with SSGJ-608
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced that its Phase III clinical study for the drug candidate SSGJ-608 has successfully met all primary endpoints (PASI 75 and sPGA 0/1), key secondary efficacy endpoints (PASI 90, PASI 100, and sPGA 0), and all…
-
3SBio Secures Exclusive Licensing Agreement for Seven Drug Candidates from Subsidiary
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has disclosed plans to enter into an exclusive licensing agreement with its parent company. Under this agreement, Guojian will grant 3SBio the Greater China rights to seven pipeline candidates, including 706, 709, HBT-2002, QY-F10, QY-F11, QY-F07, and…
-
3SBio Subsidiary Gets Green Light for SSGJ-608 Ankylosing Spondylitis Study
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has received approval from the US Food and Drug Administration (FDA) to conduct separate Phase II clinical studies for its drug candidate SSGJ-608. The molecule is set to be evaluated as a treatment for ankylosing spondylitis (AS)…
-
Sunshine Guojian’s SSGJ-608 Meets Phase III Efficacy Endpoints in Psoriasis Trial
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of 3SBio Inc. (HKG: 1530), has announced that its Phase III clinical trial for the anti-IL-17A monoclonal antibody SSGJ-608 in moderate to severe plaque psoriasis has successfully met its primary efficacy endpoints, including PASI 75 and sPGA 0/1, as well as all…
-
Sunshine Guojian Pharmaceutical Gets NMPA Approval for SSGJ-611 Phase II COPD Study
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530), has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study for SSGJ-611, an IL-4Rα monoclonal antibody (mAb), for the treatment of moderate to severe chronic obstructive pulmonary…
